阿培利司不良事件:世界卫生组织药物警戒数据库上市后研究
该研究基于WHO VigiBase数据库2019年1月至2021年6月数据,采用信息成分(IC)进行不成比例分析,评估阿培利司与不良事件的潜在关联。45-64岁组病例最多(n=203,29.55%)。共129个首选术语显示显著信号,信号最强的是高血糖(IC025=6.74)、转移性乳腺癌(IC025=5.85)和肝转移(IC025=4.70);病例数最多的是高血糖(n=595)、皮疹(n=535)和腹泻(n=475)。
要点
- 高血糖是信号最强且病例数最多的不良事件(IC025=6.74,n=595)。
- 皮疹和腹泻病例数较多(n=535和n=475),需临床关注。
- 转移性乳腺癌和肝转移显示显著信号,但可能反映适应症人群疾病进展。
核心结论
- 研究建立了阿培利司潜在相关不良事件的综合列表,信号最强的是高血糖、转移性乳腺癌和肝转移。
研究设计与样本
- 基于WHO VigiBase药物警戒数据库2019年1月1日至2021年6月30日数据的上市后不成比例分析。
主要发现
- 45-64岁组病例最多(n=203,29.55%)。
- 共129个首选术语显示显著信号。
- 信号最强的不良事件为高血糖(IC025=6.74)、转移性乳腺癌(IC025=5.85)和肝转移(IC025=4.70)。
- 病例数最多的不良事件为高血糖(n=595)、皮疹(n=535)和腹泻(n=475)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To explore and describe the adverse reaction signals in the safety reporting for alpelisib. METHODS: We performed a disproportionality analysis of the World Health Organization's VigiBase pharmacovigilance database from 1 January 2019 to 30 June 2021. Disproportionality analysis by information components (ICs) were used to evaluate the potential association between adverse events (AEs) and alpelisib. RESULTS: A total of 33 327 reports were extracted, 5695 of them were chosen with alpelisib as the suspected drug. After combining the same ID, 687 cases remained. The 45-64-years group had the most cases (n = 203, 29.55%). There were 129 Preferred Terms with significant signals. Hyperglycaemia (IC025 = 6.74), breast cancer metastatic (IC025 = 5.85) and metastases to liver (IC025 = 4.70) were the AEs with the strongest signal. AEs with the most cases were hyperglycaemia (n = 595), rash (n = 535) and diarrhoea (n = 475). CONCLUSION: We established a comprehensive list of AEs potentially associated with alpelisib. AEs with the most significant signals were hyperglycaemia, breast cancer metastatic, metastases to liver. The AEs with the most cases were hyperglycaemia, rash, diarrhoea, blood glucose increase and nausea.
引用
- Chen X, Wei L, Chi L, et al. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2021. PMID: 34786743. doi:10.1111/bcp.15143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。